 raltegravir |
| Isentress |
Pharmaceutical
company:
Merck & Co., Inc.
www.merck.com |
Pharmacologic classification: integrase inhibitor
Therapeutic classification: antiretroviral
Pregnancy risk category: C
AVAILABLE FORMS
Tablets: 400 mg
INDICATIONS AND DOSAGES
In combination with other antiretrovirals for the treatment of HIV-1 infection in treatment-experienced adults who have evidence of viral replication and HIV-1 strains resistant to multiple antiretrovirals--
Adults: 400 mg P.O. b.i.d. without regard to food.
CONTRAINDICATIONS AND CAUTIONS
Contraindicated in patients hypersensitive to any component of the drug, in treatment-naïve adults, in children, and in breast-feeding women.
Use cautiously in patients taking strong inducers of uridine diphosphate glucuronsyltransferase 1A1, patients at risk for rhabdomyolysis or myopathy, and in pregnant women. Also use cautiously during initial phase of antiretroviral therapy; patient may develop opportunistic infections (immune reconstitution syndrome). Monitor patient carefully.
INTERACTIONS
Drug-drug.
Rifampin: May decrease serum levels of raltegravir. Use together cautiously.
ADVERSE REACTIONS
CNS: asthenia, fatigue, headache, dizziness, fever.
GI: nausea, diarrhea, abdominal pain, vomiting.
GU: rhabdomyolysis.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
